ORIGINAL

Neurological Sciences

, Volume 23, Issue 1, pp 41-43

First online:

Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease

  • G. FabbriniAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • , P. BarbantiAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • , C. AuriliaAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • , C. PaulettiAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • , G. L. LenziAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • , G. MecoAffiliated withDepartment of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson’s disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.

Key words Parkinson’s disease Hallucinations Delusions Donezepil